Close
18/03/2014
The public-private partnership ESTEVE-UAB is bearing fruit
ESTEVE has announced the signing of two agreements that will enable it to progress the development of its gene therapeutic for the treatment of Sanfilippo A Syndrome and begin a phase I/II clinical trial in 2015. The agreements are with the North American biotechnology company REGENX Biosciences, LLC (REGENX) and with the French non for profit organization GÉNÉTHON.
 
Sanfilippo A is a rare and devastating neurodegenerative disease that affects approximately 1 in every 100.000 children that rarely survive past adolescence.

This gene therapy program is being developed in a public-private partnership between ESTEVE and the research team of Dr. Fàtima Bosch at the Center for Biotechnology and Gene Therapy of the Universitat Autònoma de Barcelona (UAB).

In this partnership, ESTEVE leads all activities associated with the management and protection of intellectual property, regulatory activities, the coordination and supervision of GMP manufacturing, the preclinical toxicology studies as well as all clinical development.
The CBATEG research team at the UAB brings to the partnership their scientific know-how and expertise in gene therapy including viral vector design and the development of preclinical disease models.

Press release

More news

29/09/2016 ​Barcelona, a Friendly Ecosystem for Start-Ups 22/09/2016 Barcelona, capital of particle accelerators science and technology 15/09/2016 Tech Companies With More Than $1 Million Raised: Barcelona Ranks 5th In Europe 09/09/2016 ​UB and UAB Universities Stand out in Spain According to Main International Rankings 31/08/2016 New CaixaBank's Data Center Implementation Completed In Barcelona Synchrotron Park 25/08/2016 ​Barcelona, 4th most creative city in the world
22 23 24 25 26 27 28 29 30 31 32